Bacterial vaginosis. Other inflammation of vagina and vulva
Conditions
Interventions
Intervention 1: Interventional group 1: Hypericum perforatum vaginal gel+ placebo similar metronidazole gel for 7 days (both have been produced in Drug Applied Research Center (DARC), Tabriz Universit
Metronidazole which is produced in Behvazan pharmaceutical Company will be poured in tubes with no name on them).
Treatment - Drugs
Interventional group 1: Hypericum perforatum vaginal gel+ placebo similar metronidazole gel for 7 days (both have been produced in Drug Applied Research Center (DARC), Tabriz University of Medical Sci
Interventional group 2 (Control): Metronidazole vaginal gel+ placebo similar Hypericum perforatum vaginal gel for 7 days (both have been prepared in Drug Applied Research Center (DARC), Tabriz Univers
Metronidazole which is produced in Behvazan pharmaceutical Company will be poured in tubes with no name on them)
Sponsors
Infectous Diseases Research Center
Eligibility
Sex/Gender
Female
Age
15 Years to 49 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: married women 49-15 years old with bacterial vaginosis (=3 Amsel criteria) Exclusion criteria: pregnancy; lactatation; smoking, sexually transmitted disease; abnormal vaginal bleeding; hypersensitivity to some drugs including metronidazole; history of renal transplantation; use of broad-spectrum antibiotic drugs and immunosuppressive drugs; combined contraceptive pills and hormonal drugs; anti-prostaglandins and anticoagulant drugs within the preceding 30 days and anti-epilepsy; antimigraine drugs; heart disease and kidney failure; being at risk of sexually transmitted infections and menstruation at time of diagnosis or within next 10 days
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Microbiological cure as assessed by =1 Amsel criteria. Timepoint: Ten and 30 days after starting treatment. Method of measurement: Amsel criteria. | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical cure as reported by patient and clinician. Timepoint: Ten and 30 days after starting treatment. Method of measurement: Patient and clinician report.;Adverse event. Timepoint: Within the 30 days after starting treatment. Method of measurement: Patient report and physical exam if necessary. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSakineh Mohammad-Alizadeh
Tabriz University of Medical Sciences, Nursing & Midwifery Faculty
Outcome results
None listed